• The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection 

      Trøseid, Marius; Mayerhofer, Christiane Caroline; Broch, Kaspar; Arora, Satish; Svardal, Asbjørn M.; Hov, Johannes Espolin Roksund; Andreassen, Arne K.; Gude, Einar; Karason, Kristjan; Dellgren, Gøran; Berge, Rolf Kristian; Gullestad, Lars; Aukrust, Pål; Ueland, Thor (Peer reviewed; Journal article, 2019)
      BACKGROUND: Alterations in the partly microbiota-dependent carnitine–γ-butyrobetaine (γBB)–trimethylamine N-oxide (TMAO) pathway have been linked to the progression of heart failure and atherosclerotic disease. We evaluated ...
    • Low fibre intake is associated with gut microbiota alterations in chronic heart failure 

      Mayerhofer, Cristiane C.K.; Kummen, Martin; Holm, Kristian; Broch, Kaspar; Awoyemi, Ayodeji Olawale; Vestad, Beate; Larsen, Christopher Storm; Seljeflot, Ingebjørg; Ueland, Thor; Bohov, Pavol; Berge, Rolf Kristian; Svardal, Asbjørn M.; Gullestad, Lars; Yndestad, Arne; Aukrust, Pål; Hov, Johannes Espolin Roksund; Trøseid, Marius (Journal article; Peer reviewed, 2020)
      Aims Recent reports have suggested that patients with heart failure (HF) have an altered gut microbiota composition; however, associations with diet remain largely uninvestigated. We aimed to explore differences in the ...
    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Peer reviewed, 2021)
      Background The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast ...